Zytiga

(Abiraterone acetate)

Zytiga

Drug updated on 11/15/2023

Dosage FormFilm-coated tablet (oral; 500 mg); Uncoated tablet (oral; 250 mg)
Drug ClassCYP17 inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC).
  • Indicated in combination with prednisone for the treatment of patients with metastatic high-risk castration-sensitive prostate cancer (CSPC).

Product Monograph / Prescribing Information

Document TitleYearSource
Zytiga (abiraterone acetate) Prescribing Information.2021Janssen Biotech, Inc., Horsham, PA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Risk of cognitive impairment in men with advanced prostate cancer treated with NHAs: A systematic review and network meta-analysis.2023Clinical and Translational Science
First-line therapy for metastatic castration-sensitive prostate cancer: a network meta-analysis.2022Hong Kong Journal of Radiology
Comparison of treatments for nonmetastatic castration-resistant prostate cancer: matching-adjusted indirect comparison and network meta-analysis.2022Journal of the National Cancer Institute
Efficacy and safety of therapies for advanced prostate cancer in Asia: Evidence from a systematic literature review.2022Therapeutic Advances in Medical Oncology
Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis.2022European Urology
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.2022Lancet
Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis.2022Value Health
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer.2021NICE
Efficacy and safety of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.2021Frontiers in Oncology
Steroid switch after progression on abiraterone plus prednisone in patients with metastatic castration-resistant prostate cancer: a systematic review.2021Urologic Oncology
Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis.2021Prostate Cancer and Prostatic Diseases
Optimal treatment sequencing of abiraterone acetate plus prednisone and enzalutamide in patients with castration-resistant metastatic prostate cancer: a systematic review and meta-analysis.2021Cancer Treatment Reviews
Comparison of systemic treatments for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis.2021JAMA Oncology
Treatment Sequences of Androgen Receptor–Targeted Agents for Prostate Cancer.2021CADTH
Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review.2021European Eurology Focus
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer.2020Cochrane Database of Systematic Reviews
CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials.2020Journal of Cancer and Research Therapeutics
Longitudinal model-based meta-analysis for survival probabilities in patients with castration-resistant prostate cancer.2020European Journal of Clinical Pharmacology
Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.2019Urology
Antiandrogen therapies for nonmetastatic castration-resistant prostate cancer: effectiveness and value.2018ICER
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.2018Annals of Oncology
Treatment of metastatic, castration-resistant, docetaxel-resistant prostate cancer: a systematic review of literature with a network meta-analysis of randomized clinical trials.2018Reviews on Recent Clinical Trials
Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naïve prostate cancer: a systematic review and network meta-analysis.2018European Urology
Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: a network meta-analysis.2018European Journal of Cancer
Abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 'real-life' studies.2018Therapeutic Advances in Urology
Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis.2018Expert Review of Anticancer Therapy

Clinical Practice Guidelines